- Home
- BLIN vs CANF Comparison
BLIN vs CANF Comparison
Compare BLIN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- CANF
- Stock Information
- Founded
- BLIN 2000
- CANF 1994
- Country
- BLIN United States
- CANF Israel
- Employees
- BLIN N/A
- CANF N/A
- Industry
- BLIN EDP Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- CANF Health Care
- Exchange
- BLIN Nasdaq
- CANF Nasdaq
- Market Cap
- BLIN 14.1M
- CANF 14.4M
- IPO Year
- BLIN 2007
- CANF N/A
- Fundamental
- Price
- BLIN $1.53
- CANF $1.32
- Analyst Decision
- BLIN Hold
- CANF Strong Buy
- Analyst Count
- BLIN 1
- CANF 2
- Target Price
- BLIN N/A
- CANF $14.00
- AVG Volume (30 Days)
- BLIN 121.3K
- CANF 1.2M
- Earning Date
- BLIN 02-12-2025
- CANF 12-31-2024
- Dividend Yield
- BLIN N/A
- CANF N/A
- EPS Growth
- BLIN N/A
- CANF N/A
- EPS
- BLIN N/A
- CANF N/A
- Revenue
- BLIN $15,293,000.00
- CANF $667,000.00
- Revenue This Year
- BLIN N/A
- CANF $409.56
- Revenue Next Year
- BLIN $6.35
- CANF N/A
- P/E Ratio
- BLIN N/A
- CANF N/A
- Revenue Growth
- BLIN N/A
- CANF N/A
- 52 Week Low
- BLIN $0.75
- CANF $1.29
- 52 Week High
- BLIN $1.60
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- BLIN 63.98
- CANF 24.83
- Support Level
- BLIN $1.25
- CANF $1.50
- Resistance Level
- BLIN $1.43
- CANF $1.72
- Average True Range (ATR)
- BLIN 0.10
- CANF 0.20
- MACD
- BLIN 0.01
- CANF -0.03
- Stochastic Oscillator
- BLIN 66.78
- CANF 2.83
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).